Pretax income is the income that a company earns before paying income taxes. Insmed's pretax income for the
three
months ended in Mar. 2024 was $-156.5 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-744.2 Mil.
Insmed's pretax margin was -207.29%.
During the past 13 years, Insmed's highest Pretax Margin was -178.02%. The lowest was -3295.13%. And the median was -213.63%.
Insmed Pre-Tax Income Historical Data
The historical data trend for Insmed's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Insmed's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insmed's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Insmed's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Insmed's Pre-Tax Income falls into.
Insmed Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Insmed's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-744.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed (NAS:INSM) Pre-Tax Income Explanation
Insmed's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 13 years, Insmed's highest Pretax Margin was -178.02%. The lowest was -3295.13%. And the median was -213.63%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Insmed's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INSM has been successfully added to your 